Embecta Corp. (EMBC)
Embecta Corp. (EMBC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Embecta Corp. (EMBC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Embecta Corp. (EMBC) Q2 2026 Earnings Call Transcript
Embecta Corp. (EMBC) Q2 2026 Earnings Call Transcript
Embecta Corp. (EMBC) Q1 2026 Earnings Call Transcript
Embecta Corp. (EMBC) Q1 2026 Earnings Call Transcript
Embecta Corp. (EMBC) Q4 2025 Earnings Call Transcript
Embecta Corp. ( EMBC ) Q4 2025 Earnings Call November 25, 2025 8:00 AM EST Company Participants Pravesh Khandelwal - VP & Head of Investor Relations Devdatt Kurdikar - President, CEO & Director Jake Elguicze - Senior VP & CFO Conference Call Participants Marie Thibault - BTIG, LLC, Research Division Michael Polark - Wolfe Research, LLC Anthony Petrone - Mizuho Securities USA LLC, Research Division Gracia Mahoney - BofA Securities, Research Division Presentation Operator Welcome, ladies and gentlemen, to Embecta Corp.'s Fiscal Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded, and a replay will be available on the company's website following the call.
Best Value Stocks to Buy for September 9th
JXN, EMBC and KT made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 9, 2025.
Embecta Corp. (EMBC) Q3 2025 Earnings Call Transcript
Embecta Corp. (NASDAQ:EMBC ) Q3 2025 Earnings Conference Call August 8, 2025 8:00 AM ET Company Participants Devdatt Kurdikar - President, CEO & Director Jacob P. Elguicze - Senior VP & CFO Pravesh Khandelwal - VP & Head of Investor Relations Conference Call Participants Anthony Charles Petrone - Mizuho Securities USA LLC, Research Division Gracia Leydon Mahoney - BofA Securities, Research Division Marie Yoko Thibault - BTIG, LLC, Research Division Michael K.
Embecta Corp. (EMBC) Q2 2025 Earnings Call Transcript
Embecta Corp. (NASDAQ:EMBC ) Q2 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Dev Kurdikar - President & CEO Jake Elguicze - CFO Pravesh Khandelwal - Vice VP, IR Conference Call Participants Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG Anthony Petrone - Mizuho Securities Michael Polark - Wolfe Research Operator Welcome, ladies and gentlemen, to Embecta Corp.'s fiscal second quarter 2025 earnings conference call. At this time, all participants have been placed in a listen-only mode.
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent use of EMBC's product.
Embecta Corp. (EMBC) Q1 2025 Earnings Call Transcript
Embecta Corp. (NASDAQ:EMBC ) Q1 2025 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President, Investor Relations Dev Kurdikar - President & Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley Ryan Schiller - Wolfe Research Operator Good day, and thank you for standing by. Welcome, ladies and gentlemen, to the Embecta Fiscal First Quarter 2025 Earnings Conference Call.
Embecta Corp. (EMBC) Tops Q1 Earnings and Revenue Estimates
Embecta Corp. (EMBC) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.61 per share a year ago.
3 Stocks Trading Near 52-Week High With Room to Rise Further
Investors target stocks that have been on a bullish run lately. Stocks like EMBC, NFG and REVG are seeing price strength and the momentum is likely to continue.
New Initiatives Expected To Make Embecta More Profitable
Embecta Corp.'s Q4 results showed significant net income and EPS growth as well as profitability plans, and drove up the share price. The company announced a restructuring plan to streamline operations, reduce costs by up to $65 million annually, and discontinue its insulin patch pump program. Embecta aims to strengthen its core business, expand its GLP-1 therapies portfolio, and reduce debt, positioning it for profitable growth in fiscal 2025.
